Myocarditis Associated with COVID-19: Review of a Fatal Case Report

Abstract

To date more than 774 million people worldwide were infected with the SARS-CoV-2 virus (data for February 2024), and approximately 7 million people have already died from COVID-19. Since the beginning of the COVID-19 pandemic, there have been many reports and studies on damage involvement of the SARS-CoV-2 virus not only the respiratory but cardiovascular system as well, including myocardial damage, endothelial dysfunction, acute coronary syndromes, arrhythmias, myocarditis, thromboembolism, heart failure, hypotension, cardiogenic shock and even cardiac arrest. In addition, symptomatic COVID-19 infection with a severe course is more common in comorbid patients with a history of hypertension, diabetes, obesity, cancer or chronic obstructive pulmonary disease. According to the latest literature data, the occurrence of myocarditis associated with a new coronavirus infection is more often observed in young males and is associated with a severe or even fatal prognosis, which determines the relevance of a detailed study of the pathogenetic mechanisms and therapeutic possibilities for myocardial damage prophylaxis, relieving the main disease symptoms and unfavorable prognosis prevention. To date, there are also studies indicating that acute myocarditis could be a complication not only of the infection itself, but even one of the severe post-vaccination against SARS-CoV-2complications. The purpose of this study is to research the lethal clinical case of acute infectious myocarditis complicated the course of a new coronavirus infection. A retrospective analysis of the patient’s medical history with the final diagnosis: acute coronaviral myocarditis against the background of non-compact left ventricle myocardium was carried out.